,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['bcsm', 'destinybreast03', 'breast']
#destinybreast03 safety update by after median time on treatment 6.9mon tdm1 vs 16.1mon tdxd 10.9% ild, mostly grade 1-2, no grade 4 nausea with tdxd warrants treatment with moderately ematogenic prophylaxis regimen protocols #asco22 #bcsm #oncoalert 
Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine